Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CPC Clinical Research (CPC) to offer services to Aastrom Biosciences for the commencement of Phase 3 REVIVE clinical studies for the company's expanded multicellular therapy, ixmyelocel-T.
Subscribe to our email newsletter
Under the agreement, CPC expects to manage and oversee the activities of the Eligibility Review Committee, which will be responsible to identify and confirm the eligibility of no-option and poor option patients for participation in the REVIVE CLI clinical trials.
CPC president William Hiatt said they share their commitment to advancing the REVIVE Phase 3 clinical program for ixmyelocel-T to regulatory approval and to help provide a promising therapy to CLI patients.
"Aastrom’s clinical development program is a critically important translational step in the development of cellular therapies to treat human disease, a key objective of the University of Colorado Stem Cell Center," Hiatt said.